Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.

France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

PARIS: France’s Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost ...

PARIS] France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its ...

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...